• With our proprietary protein-protein conjugation technology, UniStac, we develop highly potent tri- or tetraspecific antibodies. It allows unlimited combination of different type of molecules, such as Fv fragment, ScFv, SdFv, peptide, cytokines, growth factors, or enzymes.

  • Onegene's platform technology "UniStac" is an enzyme-mediated protein-protein conjugation technology. Unlike the traditional gene-level fusion, the combination is a truly plug-and-play between different proteins. This allows rapid expansion of promising combinations of the targets with unprecedent efficacy and safety profile.

  • The key features of UniStac are (1) nearly 100% of universal conjugation efficiency, (2) excellent retention of biological activity of the conjugated ligands, (3) superior stability (Tm, Tagg > 70°C). These are core competance that allow us to be a leader in multispecific drug development for various diseases.

  • UniStac has near 100% conjugation efficiency regardless of the type and size of ligand. In general, the ratio between two proteins to be conjugated is 1:1.2. These superior atom economy guarantees a comparable cost-competiveness to bi-specific antibody production. The UniStac conjugation produces 3-way branched structure instead of a head-to-tail structure from conventional DNA-level fusion. Therefore, all ligands harbour free ends, which minimizes steric hindrance. The conjugation generates a rigid scaffold that separates two ligands by ~4 nm. This makes it ~10 times more spacious than the corresponding hinge region of Fc structure and allows higher degree of freedom. UniStac platform contains human serum albumin or Fc, which does not require albumin-binding arm for half-life extension.

  • Onegene is constantly expanding its library of cytokines, agonist/antagonists as well as sdAbs to find the best combination for NASH(non-alcoholic steatohepatitis), immuno-oncology and fibrotic diseases.